Buy BPC-157 + TB-500 Blend, 4-30 mg Vials

Shop by goal

Popular compounds

BPC-157

TB-500

GHK-Cu Copper Peptide

Research resources

Product features

Vial strengths 4 mg · 10 mg · 20 mg · 30 mg 4 strengths, all in stock. Pick one in the selector.

Formats Single vial · 10-vial pack Price per vial and pack total update with your selection.

Form Lyophilised powder Supplied in sealed vials. Storage conditions are listed in the specifications.

This strength is out of stock. Pick another strength, or check back soon — restocks are frequent.

Available in 4 vial strengths, from 4 mg to 30 mg

Dispatched within 24 hours of confirmed payment on business days, shipped worldwide

BPC-157 + TB-500 Blend

Compare pack sizes

Tap a pack to select it

Single Vials (4)

Buy the 10-pack - save 67%/mg. Single vials welcome — checkout needs 5+ vials or any 10-vial pack - build a custom vial pack

Lab-direct quality — full packs or single-vial samples

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident. Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same source — scaled to whatever your research needs.

Scientific Research Context

What the published literature on the components of BPC-157 + TB-500 Blend examines. These are findings about each compound in the studies cited, not claims about the blend or the supplied material.

BPC-157 pharmacokinetics in rats and dogs

After a single intravenous or intramuscular dose, the elimination half-life of unchanged BPC-157 was under 30 minutes, with linear pharmacokinetics across doses. Intramuscular bioavailability was about 14-19% in rats and 45-51% in beagle dogs, and the peptide was broken down into small fragments and amino acids. [animal, rat and dog]

Thymosin beta-4 in a rat wound model

Thymosin beta-4 applied topically or intraperitoneally increased re-epithelialisation of full-thickness rat wounds by 42% at day 4 and by as much as 61% at day 7 against saline, with more collagen deposition and angiogenesis in treated wounds. In a Boyden-chamber assay it stimulated keratinocyte migration 2-3 fold. [animal, rat; in vitro]

Actin binding and cell migration

A review of thymosin beta-4 biology describes it as binding actin and promoting the migration of cells, including stem and progenitor cells, with reduced myofibroblast numbers and scarring in wounds. The review is an expert summary, not a controlled comparison. [review]

Human data on BPC-157 are thin

A pilot study reported the safety of intravenous BPC-157 infusion in a small number of people, and a systematic review has examined its use in orthopaedic sports medicine. Neither is a controlled efficacy trial of the supplied material. [human pilot; review]

Scientific Overview

In short: A fixed 1:1 research blend of BPC-157 and TB-500, offered in four strengths from 2 mg + 2 mg to 15 mg + 15 mg per vial, pairing the two compounds most often cited in peptide tissue-repair research.

Key research facts

BPC-157 and TB-500 pre-combined at a fixed 1:1 ratio in every vial

Four vial strengths in one product: 2 + 2, 5 + 5, 10 + 10 and 15 + 15 mg

BPC-157: synthetic pentadecapeptide with published rat and dog pharmacokinetic data

TB-500: synthetic fragment of thymosin beta-4, studied for actin binding and cell migration

One vial instead of two for a matched-ratio study

These points summarise lab themes, not human outcomes.

BPC-157 and TB-500 turn up together so often in repair research that a vial holding both is a sensible supply format. They are not alike. BPC-157 is a synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, about 1,419.5 Da) whose first full pharmacokinetic study, in rats and beagle dogs, reported an elimination half-life under 30 minutes and rapid breakdown into small peptide fragments and amino acids. TB-500 is the synthetic counterpart of the actin-binding region of thymosin beta-4, a naturally occurring peptide that reviews describe as released after injury and as binding actin to promote cell migration.

The four strengths differ only in quantity: the ratio is 1:1 throughout, so a 10 mg vial is 5 mg of each compound and a 30 mg vial is 15 mg of each. The printed vial codes (BB4, BB10, BB20, BB30) match the supplier list. Choosing a strength changes the amount per vial, not the composition.

The blend has no literature of its own. This page cites studies of BPC-157 and of thymosin beta-4 separately and none of the pair in a fixed vial, so treat it as a handling convenience over two separate compounds. Supplied as lyophilised powder for in-vitro and preclinical research only.

Research class: Fixed two-compound research blend

Components: BPC-157 + TB-500

Vial strengths: 4 mg, 10 mg, 20 mg, 30 mg per vial, chosen from the pack-size menu

Research focus: Tissue-repair models: wound re-epithelialisation, cell migration, angiogenesis

Evidence base: Predominantly rodent and in-vitro work on each component; a small human pilot for BPC-157; none on the blend

This blend supplies BPC-157 and TB-500 together in each vial at a fixed 1:1 ratio, in four strengths: 2 mg + 2 mg (4 mg per vial), 5 mg + 5 mg (10 mg), 10 mg + 10 mg (20 mg) and 15 mg + 15 mg (30 mg). The two compounds dominate the published peptide tissue-repair literature and are usually studied side by side, which is why a pre-combined vial is offered. BPC-157 is a synthetic pentadecapeptide; TB-500 is the synthetic actin-binding fragment of thymosin beta-4. The blend has no literature of its own: sharing a vial does not merge the two compounds' pharmacokinetics. Supplied as lyophilised research powder in sealed 10-vial packs, one strength per pack, strictly for in-vitro and preclinical research. Not for human or veterinary use.

At a glance

Compound identity Fixed two-compound research blend

Primary research focus Tissue-repair models: wound re-epithelialisation, cell migration, angiogenesis

Mechanism and receptors The blend has no combined mechanism: it is two independent compounds sharing a vial. BPC-157 is studied for tissue-protective effects with a very short plasma half-life; thymosin beta-4 for actin binding and cell migration. The mechanisms are separate and the research areas overlap.

Experimental models BPC-157 pharmacokinetics, distribution and excretion in rats and beagle dogs; Thymosin beta-4 and wound re-epithelialisation, collagen deposition and angiogenesis in rats.

Clinical research A pilot study of intravenous BPC-157 infusion in a small number of people (safety, not efficacy).

Evidence maturity Tier 3: Limited / anecdotal — The blend itself has no evidence base: this page cites no pharmacokinetic, safety or efficacy study of the two compounds as a fixed combination. Each component has a mostly animal and in-vitro record, with a small human pilot for BPC-157 and no controlled human efficacy trial cited for either. The material is supplied as unapproved laboratory material.

Research limitations Published clinical findings describe the study materials and protocols used by investigators; they do not establish the effects or safety of this research material.

Proposed Mechanism

The blend has no combined mechanism: it is two independent compounds sharing a vial. BPC-157 is studied for tissue-protective effects with a very short plasma half-life; thymosin beta-4 for actin binding and cell migration. The mechanisms are separate and the research areas overlap.

Pathway Effect Why it matters BPC-157 disposition Half-life under 30 minutes; broken down to small peptide fragments and amino acids Defines how long the intact peptide is present in the animal studies Thymosin beta-4 and actin Binds actin and is described as promoting cell migration into injured tissue A distinct route to the same repair questions Wound re-epithelialisation Faster re-epithelialisation and more angiogenesis in a rat wound model The best-quoted thymosin beta-4 animal result No shared pharmacology Each component retains its own published pharmacology Interpret results per component, not for the pair

Deeper dive for scientific readers

The pair is studied together so routinely that the combination can look like an established formulation. It is not: the pharmacokinetic work cited here covers BPC-157 alone, and the thymosin beta-4 papers cover that peptide alone. A fixed blend also fixes the ratio, which removes the ability to vary one compound while holding the other constant. If a study needs independent control of either component, use the stand-alone products instead.

Common Questions People Are Asking

What strengths does the BPC-157 + TB-500 blend come in?

Four, chosen from the pack-size menu: 4 mg per vial (2 mg BPC-157 + 2 mg TB-500, code BB4), 10 mg (5 + 5, BB10), 20 mg (10 + 10, BB20) and 30 mg (15 + 15, BB30). The ratio is 1:1 in all of them; only the amount per vial changes.

What happened to the BPC+TB 10mg Combo page?

It is now the 20 mg entry (10 mg + 10 mg, BB20) in this product. The old address redirects here, and carts and orders that named the old product resolve to the same vial.

Do BPC-157 and TB-500 work better together?

This page cites no study that compares them together with either alone. They are combined because their research areas overlap, not because a benefit of combining has been shown here. Their mechanisms are separate: BPC-157 is studied for its pharmacokinetics and tissue-protective effects, thymosin beta-4 for actin binding and cell migration.

Is a fixed blend a drawback for study design?

It can be. The ratio is fixed at 1:1, so one compound cannot be varied while the other is held constant, and the two components have different disposition profiles in the animal literature. If a design needs independent control of either one, use the stand-alone BPC-157 and TB-500 products.

Is there human data on this blend?

No study of the blend is cited. A small pilot study of intravenous BPC-157 and a systematic review of its orthopaedic use are listed in the references; neither is a controlled efficacy trial. This is laboratory research material, not for human or veterinary use.

Where can I buy BPC-157 + TB-500 Blend?

Right here - BPC-157 + TB-500 Blend is supplied directly by New-U Research Compounds on this page, as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.

How much does BPC-157 + TB-500 Blend cost?

BPC-157 + TB-500 Blend pricing is shown live on this page, per pack size - sealed 10-vial research packs, or single vials where listed (an order needs at least 5 single vials in total, or any 10-vial pack). Larger vial strengths lower the per-mg cost, and shipping is free on orders over $350.

How do I buy BPC-157 + TB-500 Blend?

Add the BPC-157 + TB-500 Blend pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step.

What payment methods can I use to buy BPC-157 + TB-500 Blend?

At checkout you can pay by card or crypto. New-U supports BTC and selected stablecoin and network-asset payments across Ethereum, Solana, TRON, Polygon, Base, BNB Chain and Linea. You choose your method after confirming your order.

How fast is shipping, and do you ship worldwide?

Yes - we ship worldwide in discreet, unmarked, tracked packaging; lyophilised peptides are stable through the tracked transit window. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.

Is it legal to buy BPC-157 + TB-500 Blend?

In the United States, BPC-157 + TB-500 Blend is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Stability Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. Notes Laboratory research material. No amount, schedule or administration guidance is published or recommended on this page.

Evidence Tier

Overall: Tier 3: Limited / anecdotal

The blend itself has no evidence base: this page cites no pharmacokinetic, safety or efficacy study of the two compounds as a fixed combination. Each component has a mostly animal and in-vitro record, with a small human pilot for BPC-157 and no controlled human efficacy trial cited for either. The material is supplied as unapproved laboratory material.

Tier 1 · Human clinical

A pilot study of intravenous BPC-157 infusion in a small number of people (safety, not efficacy)

Tier 2 · Animal

BPC-157 pharmacokinetics, distribution and excretion in rats and beagle dogs

Thymosin beta-4 and wound re-epithelialisation, collagen deposition and angiogenesis in rats

Databases & peer-reviewed sources

Last reviewed: 14 October 2026 · New-U Research Compounds

He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022. · 2022 · PMID: 36588717 · DOI: 10.3389/fphar.2022.1026182

Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. · 2025 · PMID: 40131143

Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. · 2025 · PMID: 40756949 · DOI: 10.1177/15563316251355551

Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999. · 1999 · PMID: 10469335 · DOI: 10.1046/j.1523-1747.1999.00708.x

Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012. · 2012 · PMID: 22074294 · DOI: 10.1517/14712598.2012.634793

PubMed: peer-reviewed literature on BPC-157 + TB-500 Blend

ClinicalTrials.gov: registered studies on BPC-157 + TB-500 Blend

BPC-157 + TB-500 Blend: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

Fixed 1:1 blend of BPC-157 and TB-500 in every vial

Four strengths: 2 + 2, 5 + 5, 10 + 10 and 15 + 15 mg (4, 10, 20 and 30 mg per vial)

Printed vial codes BB4, BB10, BB20 and BB30 match the supplier list

BPC-157: pentadecapeptide, about 1,419.5 Da

TB-500: synthetic fragment of thymosin beta-4

No study of the fixed blend is cited; the components are cited separately

Sold as a sealed 10-vial pack, one strength per pack

Specifications

Components BPC-157 + TB-500 Vial BB4 BPC-157 2 mg + TB-500 2 mg (4 mg per vial) Vial BB10 BPC-157 5 mg + TB-500 5 mg (10 mg per vial) Vial BB20 BPC-157 10 mg + TB-500 10 mg (20 mg per vial) Vial BB30 BPC-157 15 mg + TB-500 15 mg (30 mg per vial) Pack 10 vials, one strength per pack Analytical report None published yet Form Lyophilised powder Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light.

About the BPC-157 + TB-500 Blend: Research Guide

This product combines two compounds that are normally bought and prepared separately. Offering them in one vial removes a weighing and reconstitution step in studies that already call for both at a matched ratio, and offering four strengths lets the amount per vial follow the design of the experiment rather than the other way round.

The earlier catalogue listed this blend as two products, a 5 mg + 5 mg and a 10 mg + 10 mg version. They are now two of four entries in the strength menu here, and the old stand-alone address for the larger vial redirects to this page. The 2 mg + 2 mg and 15 mg + 15 mg vials are new.

Evidence for each component is mostly animal and in-vitro, with a small human pilot for BPC-157. The blend itself is not studied. New-U Research Compounds supplies it as laboratory research material only; nothing on this page is medical advice or a recommendation to use it in people or animals.

Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025.

Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025.

Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999.

Customer Reviews

Web fácil de usar

Entré desde el móvil y pude completar el pedido sin pelearme con la página.

- Jaridalia V***** · 22 October 2026

More in Stacks

Stacks CJC-1295 (No DAC) + Ipamorelin Blend CJC-1295 (no DAC) and ipamorelin in one vial at a fixed 1:1 ratio, in two strengths: 5 mg + 5 mg and 10 mg + 10 mg per vial. A GHRH analogue paired with a selective ghrelin-receptor agonist. CJC-1295 (No DAC) + Ipamorelin Blend →

Stacks Tesamorelin + Ipamorelin Blend Tesamorelin and ipamorelin in one vial, in three strengths: 5 mg + 5 mg, 10 mg + 4 mg and 10 mg + 5 mg per vial. A GHRH(1-44) analogue paired with a selective ghrelin-receptor agonist. Tesamorelin + Ipamorelin Blend →

Stacks Semax + Selank Blend Semax and Selank in one vial at a fixed 1:1 ratio, in two strengths: 5 mg + 5 mg and 10 mg + 10 mg per vial. Two heptapeptides developed at the same Moscow institute. Semax + Selank Blend →

Stacks Glow Glow is a three-compound research blend combining GHK-Cu, BPC-157 and TB-500 in a single vial - the copper-binding tripeptide paired with the two most-studied tissue-repair peptides. Glow →

Stacks Klow Klow is a four-compound research blend - the Glow trio of GHK-Cu, BPC-157 and TB-500 with KPV added, pairing matrix and repair signalling with the alpha-MSH anti-inflammatory fragment. Klow →

BPC-157 + TB-500 Blend vs related Stacks compounds

Compound Price Purity spec COA BPC-157 + TB-500 Blend from $140 Not published On request CJC-1295 (No DAC) + Ipamorelin Blend from $180 Not published On request Tesamorelin + Ipamorelin Blend from $220 Not published On request

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on BPC-157 + TB-500 Blend

Multi-Compound Blends research compounds

BPC-157 + TB-500 Blend research guide

Research this compound

Research guide BPC-157 + TB-500 Blend research guide The blend has no combined mechanism: it is two independent compounds sharing a vial. Read the guide →

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research